BLIS M18 ACHIEVES US FDA GRAS "NO OBJECTION" STATUS
BLIS M18
™
Achieves US FDA GRAS
“No Objection” Status
Blis Technologies Limited announces that their 2
nd
probiotic strain BLIS M18
™
, has
had the issuance of a US Food and Drug Administration ‘Letter of No Objection’.
This follows the BLIS K12 “Letter of No Objection” in 2016.
The Letter of No Objection, more commonly known as GRAS or ‘Generally
Recognized As Safe’, is another recognition of the robust data supporting Blis
probiotics.
It adds a new level of credibility for BLIS M18
™
and has the potential to open
opportunities with larger consumer food and beverage companies in the US, but also
is recognised as a relevant and credible safety assessment by other countries and
multinational companies.
Through the GRAS program, companies may submit their determination supported
by research and expert review that a specific ingredient is Generally Recognized As
Safe. The Letter of No Objection means that the FDA has reviewed the data and has
no questions regarding the notice submitted.
For further information please contact:
Brian Watson
CEO
027 705 9133
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation
with evidence-based research and the highest quality production controls enables the delivery of probiotic
solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and
gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More
information about Blis Technologies Ltd can be found at www.blis.co.nz.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PEB — Pacific Edge Limited: Annual Report & Shareholder Letter2019-06-27
“CEO’S REPORT A major highlight in FY19 has been the commercial breakthrough seen in New Zealand, with Cxbladder now in use by the majority of the national public healthcare providers and, in some cases, being incorporated into their clinical guidelines, replacing the gold st…”
- PEB — Pacific Edge Limited: Pacific Edge Reports Continued Growth in FY192019-05-28
“Company Announcement 29 May 2019 reimbursement and we expect to see a continued uplift in adoption and sales in FY20. We remain focused on the USA market which offers enormous potential for our company.” The Company’s key objectives for FY20 are as follows: • GLOBAL R…”
- PEB — Pacific Edge Limited: Cxbladder included in the NCCN Bladder Cancer Guidelines2019-07-15
“Company Announcement 15 July 2019 CXBLADDER INCLUDED IN THE LATEST NCCN BLADDER CANCER GUIDELINES IN THE USA Cancer diagnostics company, Pacific Edge (NZX: PEB), advises that Cxbladder has been included in the latest version of the National Comprehensive Cancer Network…”